Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01562782 · ClinicalTrials.gov registry record · NA

Change of Fructose to Fat in South Asians

A NA study of Diabetes and Cardiovascular Disease, sponsored by The Rogosin Institute.

Completed
Registry status
NA
Development phase
39
Enrollment target
2
Study locations

NCT01562782 is a NA study of Diabetes and Cardiovascular Disease that has completed, run by The Rogosin Institute. The registered enrollment target is 39 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01562782, a NA study of Diabetes and Cardiovascular Disease, has completed, sponsored by The Rogosin Institute.

COMPLETED
Registry status
NA
Development phase
39 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine whether hepatic de novo lipogenesis (DNL) in response to the ingestion of a mixture of glucose and fructose is greater in South Asians compared to controls (Caucasians).

Interventions

  • OTHER Fructose + Glucose Beverage

Study Locations (2)

New York

  • The Rogosin Institute - New York
  • Weill Cornell Medical College Clinical and Translational Science Center (CTSC) - New York

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2012-04-02
Est. Completion 2013-10-10
Phase NA

Sponsor

The Rogosin Institute

21 total trials

What the Registry Record Tells You About NCT01562782

The ClinicalTrials.gov registry entry for NCT01562782 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is The Rogosin Institute, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Fructose + Glucose Beverage is the first listed.

NCT01562782 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01562782 about?

NCT01562782 is a clinical study titled "Change of Fructose to Fat in South Asians". The purpose of this study is to determine whether hepatic de novo lipogenesis (DNL) in response to the ingestion of a mixture of glucose and fructose is greater in South Asians compared to controls (Caucasians).

What is the current status of trial NCT01562782?

This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2012-04-02. Estimated completion is 2013-10-10.

What conditions does trial NCT01562782 study?

This clinical trial studies the following conditions: Diabetes, Cardiovascular Disease, Dyslipidemia, Elevated Triglycerides.

What interventions are being tested in trial NCT01562782?

The interventions under investigation include: Fructose + Glucose Beverage (OTHER).

Who is sponsoring clinical trial NCT01562782?

This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01562782 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.